HF00 Stock Overview
A research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Respiratorius AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.39 |
| 52 Week High | SEK 3.58 |
| 52 Week Low | SEK 0.02 |
| Beta | 1.61 |
| 11 Month Change | 22.78% |
| 3 Month Change | 3.39% |
| 1 Year Change | -83.06% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| HF00 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1,864.5% | 1.2% | 1.0% |
| 1Y | -83.1% | -19.2% | 7.7% |
Return vs Industry: HF00 underperformed the German Biotechs industry which returned -19.2% over the past year.
Return vs Market: HF00 underperformed the German Market which returned 7.7% over the past year.
Price Volatility
| HF00 volatility | |
|---|---|
| HF00 Average Weekly Movement | 344.6% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HF00's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HF00's weekly volatility has increased from 185% to 345% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 0 | Johan Drott | www.respiratorius.com |
Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Respiratorius AB (publ) Fundamentals Summary
| HF00 fundamental statistics | |
|---|---|
| Market cap | €2.08m |
| Earnings (TTM) | -€707.34k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs HF00 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HF00 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 761.39k |
| Gross Profit | -SEK 761.39k |
| Other Expenses | SEK 7.39m |
| Earnings | -SEK 8.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HF00 perform over the long term?
See historical performance and comparison